Title:
HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN
Document Type and Number:
WIPO Patent Application WO/2023/171781
Kind Code:
A1
Abstract:
To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. The present inventors have examined compounds useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a heterocyclic compounds represented by formula (I) and formula (A) have an excellent action for inducing the degradation of G12D mutant KRAS protein and G12D mutant KRAS inhibitory activity and can be used as a therapeutic agent for pancreatic cancer, thereby completing the present invention. The heterocyclic compound or a salt thereof of the present invention can be used as a therapeutic agent for pancreatic cancer.
Inventors:
YOSHINARI TOMOHIRO (JP)
KAWAGUCHI KENICHI (JP)
KAWAMINAMI EIJI (JP)
ISHIOKA HIROKI (JP)
WATANABE HIDEYUKI (JP)
IMAIZUMI TOMOYOSHI (JP)
HAMAGUCHI HISAO (JP)
TAKAHASHI FUMIE (JP)
MORIKAWA TAKAHIRO (JP)
KURAMOTO KAZUYUKI (JP)
NAGASHIMA TAKEYUKI (JP)
INAMURA KOHEI (JP)
KAWAGUCHI KENICHI (JP)
KAWAMINAMI EIJI (JP)
ISHIOKA HIROKI (JP)
WATANABE HIDEYUKI (JP)
IMAIZUMI TOMOYOSHI (JP)
HAMAGUCHI HISAO (JP)
TAKAHASHI FUMIE (JP)
MORIKAWA TAKAHIRO (JP)
KURAMOTO KAZUYUKI (JP)
NAGASHIMA TAKEYUKI (JP)
INAMURA KOHEI (JP)
Application Number:
PCT/JP2023/009205
Publication Date:
September 14, 2023
Filing Date:
March 10, 2023
Export Citation:
Assignee:
ASTELLAS PHARMA INC (JP)
International Classes:
C07D403/14; A61K31/4995; A61K31/506; A61K31/517; A61P1/18; A61P35/00; C07D407/14; C07D413/14; C07D417/14; C07D487/08
Domestic Patent References:
| WO2021107160A1 | 2021-06-03 | |||
| WO2021041671A1 | 2021-03-04 | |||
| WO2017172979A1 | 2017-10-05 | |||
| WO2022173032A1 | 2022-08-18 | |||
| WO2022173033A1 | 2022-08-18 |
Foreign References:
| JP6587116B2 | 2019-10-09 |
Attorney, Agent or Firm:
YAMAMOTO, Osamu et al. (JP)
Download PDF: